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Treatment guidelines recommend the use of peginterferon alfa-2b or peginterferon
alfa-2a in combination with ribavirin for chronic hepatitis C virus (HCV) infection.
However, these regimens have not been adequately compared.
Methods

At 118 sites, patients who had HCV genotype 1 infection and who had not previously
been treated were randomly assigned to undergo 48 weeks of treatment with one of
three regimens: peginterferon alfa-2b at a standard dose of 1.5 μg per kilogram of
body weight per week or a low dose of 1.0 μg per kilogram per week, plus ribavirin
at a dose of 800 to 1400 mg per day, or peginterferon alfa-2a at a dose of 180 μg per
week plus ribavirin at a dose of 1000 to 1200 mg per day. We compared the rate of
sustained virologic response and the safety and adverse-event profiles between the
peginterferon alfa-2b regimens and between the standard-dose peginterferon alfa2b regimen and the peginterferon alfa-2a regimen.
Results

Among 3070 patients, rates of sustained virologic response were similar among the
regimens: 39.8% with standard-dose peginterferon alfa-2b, 38.0% with low-dose
peginterferon alfa-2b, and 40.9% with peginterferon alfa-2a (P = 0.20 for standarddose vs. low-dose peginterferon alfa-2b; P = 0.57 for standard-dose peginterferon
alfa-2b vs. peginterferon alfa-2a). Estimated differences in response rates were 1.8%
(95% confidence interval [CI], −2.3 to 6.0) between standard-dose and low-dose peg
interferon alfa-2b and −1.1% (95% CI, −5.3 to 3.0) between standard-dose peginterferon alfa-2b and peginterferon alfa-2a. Relapse rates were 23.5% (95% CI, 19.9 to
27.2) for standard-dose peginterferon alfa-2b, 20.0% (95% CI, 16.4 to 23.6) for lowdose peginterferon alfa-2b, and 31.5% (95% CI, 27.9 to 35.2) for peginterferon alfa2a. The safety profile was similar among the three groups; serious adverse events
were observed in 8.6 to 11.7% of patients. Among the patients with undetectable
HCV RNA levels at treatment weeks 4 and 12, a sustained virologic response was
achieved in 86.2% and 78.7%, respectively.
Conclusions

In patients infected with HCV genotype 1, the rates of sustained virologic response
and tolerability did not differ significantly between the two available peginterferon–
ribavirin regimens or between the two doses of peginterferon alfa-2b. (ClinicalTrials.
gov number, NCT00081770.)
n engl j med 361;6
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H

epatitis C virus (HCV) chronically
infects approximately 180 million people
worldwide1 and is a frequent cause of liver
disease, including liver failure and hepatocellular
carcinoma.2 HCV treatment is recommended for
persons at the greatest risk for progression of liver
disease.3 On the basis of noncomparative studies
demonstrating similar safety and efficacy between
the two treatments,4,5 consensus guidelines recommend the use of either peginterferon alfa-2b
or peginterferon alfa-2a in combination with ribavirin for the treatment of chronic hepatitis C. However, differences between the peginterferons with
respect to structural modifications and dosing
(weight-adjusted vs. fixed) may lead to important
differences in clinical outcomes, and there is some
evidence of such differences.6-9 Randomized, comparative effectiveness trials are necessary to provide
patients with evidence-based treatment options.
The Individualized Dosing Efficacy vs. Flat
Dosing to Assess Optimal Pegylated Interferon
Therapy (IDEAL) study was initiated to compare
standard-dose and low-dose regimens of peginterferon alfa-2b, plus ribavirin, after it was observed
that both dose levels yielded similar rates of sustained virologic response in the absence of ribavirin.10 A third treatment group, peginterferon
alfa-2a plus ribavirin, was added to the study because (in addition to standard-dose peginterferon alfa-2b plus ribavirin) it is the other approved
regimen. The objective was to compare the safety
and efficacy of the two standard regimens and
the experimental low-dose peginterferon alfa-2b
regimen.

Me thods
Study Patients

We enrolled patients from 118 centers in the United States. Eligible patients were 18 years of age or
older, had compensated liver disease due to chronic HCV genotype 1 infection and a detectable plasma HCV RNA level, and had not been previously
treated for hepatitis C infection. The patients had
an absolute neutrophil count of 1500 or more per
cubic millimeter, a platelet count of 80,000 or
more per cubic millimeter, and hemoglobin level
of 12 g (for women) or 13 g (for men) or more per
deciliter. Patients were excluded if they had coinfection with human immunodeficiency virus or
hepatitis B, any other cause of liver disease, poorly
controlled diabetes mellitus (glycated hemoglobin value >8.5%), morbid obesity (weight >125 kg),
n engl j med 361;6

severe depression or a severe psychiatric disorder,
or active substance abuse. All patients had undergone liver biopsy within 3 years before screening.
A pathologist at the central site, who was unaware
of the treatment assignments, reviewed all the
biopsy specimens and determined the METAVIR
fibrosis stage and inflammatory grade, as well as
the percentage of the tissue containing hepatocytes with steatosis.11
Study Oversight

The study sponsor and the academic principal investigators were jointly responsible for the study
design, protocol, statistical analysis plan, and data
analysis. The principal investigators had unrestricted access to the data, wrote the manuscript, and
vouch for the accuracy and integrity of the data
and analyses. A publication committee comprising the academic principal investigators and three
independent experts prepared the prespecified
data-analysis plan and ensured the unbiased interpretation of the data.
Study Design

Patients were randomly assigned, in a 1:1:1 ratio
and with the use of an interactive voice system, to
one of the three treatment groups and were stratified according to HCV RNA level (≤600,000 IU
per milliliter or >600,000 IU per milliliter) and
self-reported race (black or nonblack). The three
treatment groups were as follows: peginterferon
alfa-2b at the standard dose, 1.5 μg per kilogram
of body weight per week, or at a lower dose, 1.0
μg per kilogram per week, both in combination
with oral ribavirin at a dose according to body
weight (40 to 65 kg, 800 mg per day; >65 to 85 kg,
1000 mg per day; >85 to 105 kg, 1200 mg per day;
and >105 to 125 kg, 1400 mg per day); or peginterferon alfa-2a at a dose of 180 μg per week, plus
oral ribavirin at a dose of 1000 to 1200 mg per
day, according to body weight (<75 kg, 1000 mg
per day; ≥75 kg, 1200 mg per day).
The study was double-blinded with regard to
the dose of peginterferon alfa-2b. For patients receiving peginterferon alfa-2a, the dose of ribavirin was determined on the basis of prescribing
information from the Food and Drug Administration (FDA). Because weight-based ribavirin dosing
was not approved by the FDA for use with peginterferon alfa-2b when the study was initiated, the
dose of ribavirin administered in the two groups
receiving peginterferon alfa-2b was calculated to
deliver a mean (±SD) of 13±2 mg per kilogram per
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day, on the basis of data derived from previous trials and from the product information from the
European Medicines Agency.4,7,12 Patients underwent treatment for up to 48 weeks and follow-up
for 24 weeks. The study was approved by each center’s institutional review board and was conducted
in accordance with provisions of the Declaration
of Helsinki and Good Clinical Practice guidelines.
Efficacy Assessments

HCV RNA levels were measured with the use of
the Cobas TaqMan assay (Roche), which has a lower limit of quantitation of 27 IU per milliliter.
Measurements were obtained at screening visits
1 and 2 (baseline); weeks 2, 4, 12, 24, and 48 during the treatment period; and follow-up weeks 4,
12, and 24. Per established guidelines, patients
with an insufficient virologic response at 12 weeks
(a detectable HCV RNA level and a decrease of
<2 log10 IU from the baseline level) or at 24 weeks
(a detectable HCV RNA level) were considered to
have treatment failure, and therapy was discontinued.
Safety Assessments

Adverse events were graded by the investigators as
mild, moderate, severe, or life-threatening, according to a modified World Health Organization grading system. Non–life-threatening adverse events
were managed by reduction of the dose of peginterferon alfa or ribavirin (or both). The peginterferondose reduction was a two-step process: the dose
was reduced if the neutrophil count was below
750 per cubic millimeter, and treatment with both
drugs was permanently discontinued if the neutrophil count was below 500 per cubic millimeter. For patients receiving peginterferon alfa-2b,
the ribavirin-dose reduction occurred in two steps,
as established by Jacobson et al.7 The first step
was a reduction of either 200 mg (in patients receiving 800 to 1200 mg of ribavirin per day) or
400 mg (in patients receiving 1400 mg per day);
the second step was reduction by another 200 mg,
if required for resolution of the adverse event. For
patients receiving peginterferon alfa-2a, ribavirindose reduction consisted of a reduction to 600 mg
per day, on the basis of FDA-approved prescribing
information. For all patients, ribavirin-dose reduction was required if the hemoglobin level was
less than 10 g per deciliter; treatment with both
drugs was permanently discontinued if the level
was below 8.5 g per deciliter. In patients with a
582
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hemoglobin level less than 10 g per deciliter, use
of erythrocyte-stimulating agents was permitted
after ribavirin-dose reduction. Drug doses could
be increased once the cytopenia resolved (i.e., the
neutrophil count was ≥750 per cubic millimeter
or the hemoglobin level was ≥10 g per deciliter).
End Points

Analyses included data from all patients who underwent randomization and who received at least
one dose of study medication. The primary end
point was a sustained virologic response, defined
as undetectable HCV RNA levels 24 weeks after the
completion of therapy. If the 24-week post-treatment HCV RNA measurement was missing, the
12-week post-treatment level was used. (This was
done for 38, 21, and 25 patients receiving standard-dose and low-dose peginterferon alfa-2b and
peginterferon alfa-2a, respectively, all of whom
had had undetectable HCV RNA at 12 weeks after
treatment.)
The study involved two primary comparisons:
standard-dose versus low-dose peginterferon alfa2b regimens and standard-dose peginterferon alfa2b versus peginterferon alfa-2a. Secondary end
points included the rates of virologic response during the treatment phase and relapse, defined as
an undetectable HCV RNA level at the end of the
treatment phase, with a detectable HCV RNA level
during the follow-up period.
Statistical Analysis

For both primary comparisons, the trial was designed as a superiority study to detect clinically
meaningful differences in the rates of sustained virologic response among the three regimens. The
study had a statistical power of 80% to detect a
significant absolute difference in rates of sustained
virologic response of 6.5% between the standarddose and low-dose peginterferon alfa-2b regimens
and of 7% between the standard-dose peginterferon alfa-2b regimen and the peginterferon alfa-2a
regimen. A one-sided test was used to compare the
two peginterferon alfa-2b regimens, with an assumption that the standard-dose regimen would
be at least as effective as the low-dose regimen.
A two-sided test was used to compare standarddose peginterferon alfa-2b and peginterferon alfa2a. Because there were two primary treatment comparisons, the Holm–Bonferroni method was used
to maintain the overall type 1 error rate at 0.05.
According to this method, the lowest P value must
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be below 0.025 to be considered to indicate statistical significance. If this criterion is met, then
the higher P value must be below 0.05 to be considered to indicate statistical significance. If the
lowest P value is greater than 0.025, no other tests
are performed.
P values for the two primary treatment comparisons were calculated on the basis of a logisticregression model controlling for the stratification
factors (race and baseline HCV RNA level). Since
neither of the two comparisons was significant,
all P values are considered to be nominal and are
labeled as such. Similarly, nominal two-sided 95%
confidence intervals are reported, calculated for
the two primary comparisons according to a Man
tel–Haenszel approach controlling for the stratification factors. Summary statistics are reported
for each of the three treatment regimens for subgroups of patients defined by prespecified baseline characteristics and one characteristic defined
post hoc (baseline fasting glucose level). Multivariable logistic-regression analyses involving treatment regimen, prespecified baseline characteristics, and three post hoc factors (baseline fasting
glucose level, hemoglobin value, and platelet count)
were performed to study sustained virologic response and relapse. A stepwise procedure was
used to identify independent predictors of sustained virologic response and relapse (with P = 0.05
as the threshold level for variables to be entered
into and retained in the final model). This type
of approach was prespecified in the analysis plan
for sustained virologic response but not for relapse. As was prespecified, we also explored the
relationship between the magnitude and rapidity
of virologic response during the treatment phase
and the probability of achieving a sustained virologic response.

R e sult s
Characteristics of the Study Patients

Between March 2004 and June 2006, a total of 4469
patients were screened, and 3070 underwent randomization and treatment (Fig. 1). Baseline demographic characteristics were balanced among
the three treatment groups (Table 1). The majority of patients were men in their 40s; 18.6% of
the patients were black; and the mean body weight
was 83.4 kg. After stratification on the basis of
body weight, 1061 of 2035 patients (52.1%) receiving peginterferon alfa-2b were assigned to receive
n engl j med 361;6

the same dose of ribavirin as the corresponding
patients receiving peginterferon alfa-2a, whereas
773 of the 2035 patients (38.0%) were assigned a
lower dose of ribavirin, and 201 of the 2035 (9.9%)
were assigned a higher dose. During the treatment
period, the mean and median daily ribavirin doses
received were significantly higher among patients
receiving peginterferon alfa-2a than those in either
peginterferon alfa-2b group, regardless of ribavirindose reduction, use of erythrocyte-stimulating
agents, or efficacy outcome (sustained virologic response, relapse, or nonresponse). The proportion of
patients who received, on average, more than 13 mg
of ribavirin per kilogram per day was greater in the
peginterferon alfa-2a group (56.0%) than in either peginterferon alfa-2b group (29.1% in the standard-dose group and 32.6% in the low-dose group)
(P<0.001 for each comparison).
Efficacy

The rates of sustained virologic response did not
differ significantly among the three treatment
groups, with a rate of 39.8% (95% confidence interval [CI], 36.8 to 42.8) for standard-dose peginterferon alfa-2b, 38.0% (95% CI, 35.0 to 41.0) for lowdose peginterferon alfa-2b, and 40.9% (95% CI,
37.9 to 43.9%) for peginterferon alfa-2a, (P = 0.20
for standard-dose vs. low-dose peginterferon alfa2b; P = 0.57 for standard-dose peginterferon alfa2b vs. peginterferon alfa-2a) (Table 2). Estimated
differences in response rates were 1.8% (95% CI,
−2.3 to 6.0) between standard-dose and low-dose
peginterferon alfa-2b and −1.1% (95% CI, −5.3 to
3.0) between standard-dose peginterferon alfa-2b
and peginterferon alfa-2a. Therefore, the two primary trial end points of superiority were not met.
Response rates at the end of the treatment phase
were higher with peginterferon alfa-2a than with
either peginterferon alfa-2b regimen, but the virologic relapse rate was also higher. In all three
groups, HCV RNA suppression at treatment weeks
4 and 12 was strongly associated with achievement
of sustained virologic response (Table 3). Fewer
than 5% of patients who had a reduction from
the baseline HCV RNA level of less than 1 log10
IU per milliliter at week 4 also had a sustained
virologic response. A prolonged time (>12 weeks
of therapy) to undetectable HCV RNA level was
associated with a higher likelihood of relapse after treatment (Table 3). Stepwise multivariable
logistic-regression analyses identified several baseline factors as independent predictors of sus-
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1386 Were excluded
1038 Were ineligible for protocol
215 Declined to participate
92 Were lost to follow-up
38 Were noncompliant with
regard to protocol
3 Had adverse event

3083 Underwent randomization

13 Underwent randomization but
were not treated

3070 Were treated
1019 Were assigned to standard-dose
peginterferon alfa-2b+ribavirin
1016 Were assigned to low-dose
peginterferon alfa-2b+ribavirin
1035 Were assigned to peginterferon
alfa-2a+ribavirin

1416 Discontinued treatment
830 Had treatment failure
362 Had adverse event
224 Had other reason

383 Never entered
follow-up

2687 Entered follow-up
892 Were receiving standard-dose
peginterferon alfa-2b+ribavirin
882 Were receiving low-dose
peginterferon alfa-2b+ribavirin
913 Were receiving peginterferon
alfa-2a+ribavirin

270 Discontinued follow-up
163 Were lost to follow-up
9 Had adverse event
98 Had other reason

2417 Completed follow-up
812 Were receiving standard-dose
peginterferon alfa-2b+ribavirin
779 Were receiving low-dose
peginterferon alfa-2b+ribavirin
826 Were receiving peginterferon
alfa-2a+ribavirin

584
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Figure 1. Screening, Treatment, and Follow-up
of the Study Patients.
Patients with chronic hepatitis C virus (HCV) genotype
1 infection were randomly assigned to receive 48 weeks
of treatment with either peginterferon alfa-2b at a standard dose (1.5 μg per kilogram of body weight per
week) or a low dose (1.0 μg per kilogram per week),
plus ribavirin at a dose of 800 to 1400 mg per day, or
peginterferon alfa-2a at a dose of 180 μg per week plus
ribavirin at a dose of 1000 to 1200 mg per day. Patients
with an inadequate virologic response at 12 weeks
(predefined as a log10 decrease of <2 from the baseline
HCV RNA level) or at 24 weeks (predefined as detectable HCV RNA) were considered to have had treatment
failure, and therapy was discontinued. All patients were
eligible to undergo follow-up for up to 24 weeks after
treatment.

4469 Patients were screened

1654 Completed treatment
540 Were receiving standard-dose
peginterferon alfa-2b+ribavirin
493 Were receiving low-dose
peginterferon alfa-2b+ribavirin
621 Were receiving peginterferon
alfa-2a+ribavirin

of

tained virologic response: baseline HCV RNA level
(≤600,000 IU per milliliter), race (nonblack), minimal fibrosis (METAVIR score of F0, F1, or F2), absence of steatosis, normal baseline fasting glucose level, and elevated baseline serum alanine
aminotransferase level. Using the same method,
we found that these factors were independently
associated with relapse, as were age over 40 years
and peginterferon alfa-2a treatment (Table 1 of
the Supplementary Appendix, available with the
full text of this article at NEJM.org).
Ribavirin Dosing

Rates of sustained virologic response were similar among the three treatment groups, within the
subgroups of patients receiving the same dose of
ribavirin (those weighing >65 to <75 kg and those
weighing >85 to 105 kg) (Table 2). The ribavirin
dose was reduced, owing to an adverse event, in
30.2% of patients. The rate of sustained virologic
response among these patients was 52.2% in the
peginterferon alfa-2a, 51.8% in the standard-dose
peginterferon-2b group, and 49.3% in the lowdose peginterferon alfa-2b group. In comparison,
the rate of sustained virologic response was higher
among patients who had a hemoglobin level that
was less than 10 g per deciliter during the treatment phase but who required a ribavirin-dose reduction, as compared with those with levels of 10 g
per deciliter or above: 48.8% (422 of 865 patients)
versus 36.7% (793 of 2158 patients) (P<0.001).
Safety

The types and frequencies of adverse events were
similar among the three groups (Table 4). The
most common adverse events included influenza1st
2nd
n engl j med
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Table 1. Baseline Demographic and Disease Characteristics of the Study Patients, According to Treatment Group.*
Low-Dose Peginterferon
Alfa-2b + Ribavirin
(N = 1016)

Characteristic

Standard-Dose Peginterferon
Alfa-2b + Ribavirin
(N = 1019)

Peginterferon
Alfa-2a + Ribavirin
(N = 1035)

Age — yr

47.5±8.1

47.5±7.8

47.6±8.2

Weight — kg

83.4±15.8

84.0±16.5

82.8±16.6

Male sex — no. (%)

607 (59.7)

613 (60.2)

613 (59.2)

White

724 (71.3)

732 (71.8)

733 (70.8)

Black

187 (18.4)

183 (18.0)

200 (19.3)

Hispanic

68 (6.7)

79 (7.8)

66 (6.4)

Asian-American

21 (2.1)

10 (1.0)

20 (1.9)

American Indian

5 (0.5)

3 (0.3)

3 (0.3)

Race or ethnic group — no. (%)†

Other

11 (1.1)

12 (1.2)

13 (1.3)

815 (80.2)

822 (80.7)

842 (81.4)

Log10 value (IU/ml)

6.32±0.70

6.32±0.69

6.34±0.64

>600,000 IU/ml — no. (%)

830 (81.7)

836 (82.0)

852 (82.3)

107 (10.5)

111 (10.9)

110 (10.6)

ALT above upper limit of the normal
range — no. (%)
HCV RNA‡

METAVIR fibrosis score of F3 or F4 —
no. (%)§
Steatosis — no. (%)
0

353 (34.7)

391 (38.4)

373 (36.0)

>0 to ≤5%

464 (45.7)

450 (44.2)

457 (44.2)

>5%

154 (15.2)

139 (13.6)

142 (13.7)

45 (4.4)

39 (3.8)

63 (6.1)

Missing data
HCV genotype 1 subtype — no. (%)
1

2 (0.2)

1a

637 (62.7)

648 (63.6)

634 (61.3)

1b

358 (35.2)

353 (34.6)

374 (36.1)

19 (1.9)

16 (1.6)

23 (2.2)

1a and 1b

2 (0.2)

4 (0.4)

* Plus–minus values indicate means ±SD. There were no significant differences among the groups with regard to baseline characteristics. ALT denotes alanine aminotransferase, and HCV hepatitis C virus.
† Race or ethnic group was self-reported.
‡ Hepatitis C virus level was determined with the use of the Cobas TaqMan assay (Roche), for which the lower limit of
quantitation is 27 IU per milliliter.
§ Percutaneous liver-biopsy specimens obtained before treatment were evaluated with regard to METAVIR fibrosis staging by a pathologist at the central site. The METAVIR scoring system classifies fibrosis according to a 5-point scale: F0
indicates no fibrosis; F1, portal fibrosis without septa; F2, portal fibrosis with few septa; F3, portal fibrosis with numerous septa but without cirrhosis; and F4, portal fibrosis with cirrhosis.

like symptoms, depression, and the hematologic
events of anemia and neutropenia. The proportions
of patients with neutropenia who met the criterion for peginterferon-dose reduction (a neutrophil count of <750 and ≥500 per cubic millimeter
were 21.1% receiving peginterferon alfa-2a, 19.4%
receiving standard-dose peginterferon alfa-2b, and
12.5% receiving low-dose peginterferon alfa-2b.
n engl j med 361;6

However, only 2.1 to 5.9% of patients met the discontinuation criterion based on neutropenia. The
proportion of patients meeting the hemoglobin
criterion for ribavirin-dose reduction (a hemoglobin level <10 and ≥8.5 g per deciliter) was somewhat higher with standard-dose peginterferon alfa2b (28.2%) and peginterferon alfa-2a (25.8%) than
with low-dose peginterferon alfa-2b (23.2%); only
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500 (49.2)

48 (end of treatment)
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147/409 (35.9)
239/607 (39.4)

Female

Male

White

140/383 (36.6)
35/78 (44.9)

75 to 85 kg

>85 to 105 kg

>105 to 125 kg

302/720 (41.9)
84/296 (28.4)

<5.6 mmol/liter

≥5.6 mmol/liter

Fasting glucose

66/165 (40.0)
93/250 (37.2)

>65 to <75 kg

52/140 (37.1)

40 to 65 kg

Weight — kg**

31/187 (16.6)
316/724 (43.6)

Black

74/140 (52.9)

83/279 (29.7)

323/739 (43.7)

45/107 (42.1)

142/348 (40.8)

99/272 (36.4)

55/150 (36.7)

65/142 (45.8)

319/732 (43.6)

42/183 (23.0)

332/879 (37.8)

100/304 (32.9)

322/730 (44.1)

42/108 (38.9)

117/322 (36.3)

123/270 (45.6)

72/175 (41.1)

69/160 (43.1)

324/733 (44.2)

52/200 (26.0)

332/872 (38.1)

91/163 (55.8)

246/613 (40.1)

177/422 (41.9)

423 (40.9)

193/612 (31.5)

667 (64.4)

638 (61.6)

466 (45.0)

123 (11.9)

44 (4.3)

Peginterferon
Alfa-2a + Ribavirin
(N = 1035)

0.20

0.04

0.12

0.03

0.002

0.37

0.57

<0.001

<0.001

0.01

0.73

0.83

Standard-Dose
Standard-Dose
vs. Low-Dose
Peginterferon Alfa-2b vs.
Peginterferon Alfa-2b
Peginterferon Alfa-2a

P Value†

of

Race‖

72/154 (46.8)
314/862 (36.4)

>40 yr

226/613 (36.9)

180/406 (44.3)

406 (39.8)

123/523 (23.5)

542 (53.2)

519 (50.9)

407 (39.9)

116 (11.4)

45 (4.4)

Standard-Dose Peginterferon
Alfa-2b + Ribavirin
(N = 1019)

n e w e ng l a n d j o u r na l

≤40 yr

Age

Sex

Sustained virologic response according to baseline
characteristics — no./total no. (%)¶

386 (38.0)

491 (48.3)

24

Sustained virologic response — no. (%)§

366 (36.0)

12

95/475 (20.0)

79 (7.8)

4

Relapse rate — no./total no. (%)‡

42 (4.1)

2

According to treatment wk

Virologic response — no. (%)

Variable

Low-Dose Peginterferon
Alfa-2b + Ribavirin
(N = 1016)

Table 2. Virologic Response during and after Treatment, According to Treatment Group.*
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Elevated

Yes

182/448 (40.6)

n engl j med 361;6

64/197 (32.5)

43/216 (19.9)

175/338 (51.8)

224/338 (66.3)

191/441 (43.3)

215/578 (37.2)

23/111 (20.7)

366/869 (42.1)

111/183 (60.7)

295/836 (35.3)

203/589 (34.5)

186/391 (47.6)

342/822 (41.6)

72/193 (37.3)

63/227 (27.8)

168/322 (52.2)

238/322 (73.9)

322/757 (42.5)

101/278 (36.3)

26/110 (23.6)

376/862 (43.6)

120/183 (65.6)

303/852 (35.6)

218/599 (36.4)

184/373 (49.3)

351/842 (41.7)

*		 Virologic response was defined as an undetectable hepatitis C virus (HCV) RNA level (i.e., a level <27 IU per milliliter, as measured with the use of the Cobas TaqMan assay [Roche]).
Percentages are based on the total number of patients in the group unless otherwise indicated. To convert the values for fasting glucose to milligrams per deciliter, divide by 0.05551.
ALT denotes alanine aminotransferase.
†		 Nominal P values (one-sided for low-dose vs. standard-dose peginterferon alfa-2b and two-sided for standard-dose peginterferon alfa-2b vs. peginterferon alfa-2a) were obtained from
a logistic-regression model with virologic response as the dependent variable and treatment group and the stratification factors (race and baseline virologic load) as independent variables. Since the two primary treatment comparisons for sustained virologic response are not significant (both P values >0.025), no other comparisons can be considered significant,
on the basis of the multiplicity strategy prespecified in the trial design.
‡		 Relapse was defined as undetectable HCV RNA levels at the end of treatment but detectable levels during the follow-up period. The 95% confidence intervals (CIs) for the rates of relapse were 19.9 to 27.2% for standard-dose peginterferon alfa-2b, 16.4 to 23.6% for low-dose peginterferon alfa-2b, and 27.9 to 35.2% for peginterferon alfa-2a. The difference in the
rate of relapse between standard-dose peginterferon alfa-2b and peginterferon alfa-2a was –8.0% (95% CI, –13.2 to –2.8) and between standard-dose and low-dose peginterferon alfa2b was 3.5% (95% CI, –1.6% to 8.6%).
§		 Sustained virologic response was defined as undetectable HCV RNA levels at the end of the follow-up period. The 12-week post-treatment HCV RNA level was used if the 24-week
post-treatment level was missing (as specified in the protocol). The numbers of patients who had undetectable HCV RNA levels 12 weeks after treatment but who missed the 24-week
post-treatment visit were 21, 38, and 25 for low-dose peginterferon alfa-2b, standard-dose peginterferon alfa-2b, and peginterferon alfa-2a, respectively. The difference in the rate of response between standard-dose peginterferon alfa-2b and peginterferon alfa-2a was −1.1% (95% CI, −5.3 to 3.0) and the difference in the rate between standard-dose and low-dose
peginterferon alfa-2b was 1.8% (95% CI, −2.3 to 6.0).
¶		 All characteristics included in this table were identified in the subgroup-analysis section of the statistical-analysis plan, except for baseline fasting glucose level (a post hoc addition).
P values for the interaction between treatment group and baseline characteristics are presented in Table 2 of the Supplementary Appendix, available with the full text of this article at
NEJM.org.
‖		 Race was self-reported.
** Patients in different weight categories received different doses of ribavirin, according to body weight and the assigned peginterferon regimen: those weighing 40 to 65 kg in the
peginterferon alfa-2b groups received 800 mg of ribavirin daily and in the peginterferon alfa-2a group received 1000 mg of ribavirin daily, those weighing more than 65 and less than
75 kg in any of the three groups received 1000 mg of ribavirin daily, those weighing 75 to 85 kg in the peginterferon alfa-2b groups received 1000 mg of ribavirin daily and in the
peginterferon alfa-2a group received 1200 mg daily, those weighing more than 85 kg and up to 105 kg received 1200 mg of ribavirin daily in any of the three groups, and those weighing more than 105 kg in the peginterferon alfa-2b groups received 1400 mg of ribavirin daily and in the peginterferon alfa-2a group received 1200 mg of ribavirin daily.
†† The total numbers of patients for whom we had data on histologic findings of hepatic steatosis and fibrosis scores are the subgroups of patients for whom the liver-biopsy specimen
was deemed adequate for assessment by the pathologist at the central site.
‡‡ Response rates in subgroups with ribavirin dose reduction were calculated for all patients whose dose of ribavirin was reduced owing to an adverse event at any time or for any duration during the treatment phase of the study.

23/155 (14.8)

132/268 (49.3)

Sustained virologic response

Relapse

160/268 (59.7)

At end of treatment

Response rates in subgroups with ribavirin dose reduction — no./total no. (%)‡‡

204/568 (35.9)

>13 mg/kg/day

32/107 (29.9)

≤13 mg/kg/day

Assigned ribavirin dose

F3 or F4

F0, F1, or F2

335/864 (38.8)

109/186 (58.6)

≤600,000 IU/ml

METAVIR fibrosis score††

277/830 (33.4)

>600,000 IU/ml

Virologic load

161/353 (45.6)
206/618 (33.3)

No

Hepatic steatosis††

73/201 (36.3)
313/815 (38.4)

Normal

ALT
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The

n e w e ng l a n d j o u r na l

2.1 to 3.8% of patients met the discontinuation
criterion (hemoglobin level <8.5 g per deciliter).
Most psychiatric adverse events were mild or
moderate and were not treatment-limiting; however, 1.8 to 2.6% of patients did discontinue treatment. Twelve patients (0.4%) died during the study:
seven during the treatment period and five during
or after the follow-up period. Two of these deaths
were considered by the investigator to be possibly
related to study medications: a suicide at 6 months
after the end of treatment with standard-dose
peginterferon alfa-2b and a myocardial infarction
during treatment with peginterferon alfa-2a.

Discussion
Treatment with peginterferon alfa-2a or peginterferon alfa-2b, plus ribavirin, for 48 weeks is recommended for patients infected with HCV genotype 1, the most common variant in the United
States and Europe.13 Despite this recommendation, few data comparing these treatment regimens are available. Accordingly, several findings
of our large, randomized comparative study affect the care of these patients.
The safety and adverse-event profiles and the
efficacy data were similar among patients treated with low-dose or standard-dose peginterferon
alfa-2b or peginterferon alfa-2a, in combination
with differing ribavirin regimens. The finding that
low-dose peginterferon alfa-2b resulted in a similar rate of sustained virologic response as the
other regimens was unexpected. Since monotherapy with standard-dose peginterferon alfa-2b has
been associated with higher rates of virologic response during the treatment period,10 we aimed
to test the hypothesis that use of standard-dose
peginterferon alfa-2b with ribavirin would result
in a higher rate of sustained virologic response
than with the low-dose regimen. Although our
data do not support this hypothesis, a significant
interaction between treatment group and sex
(P = 0.01) (Table 2 in the Supplementary Appendix)
suggests that women may have higher rates of
sustained virologic response with standard-dose
than with low-dose peginterferon alfa-2b. Although the interaction with race was not significant, blacks tended to have higher rates of sustained virologic response with the standard dose
of peginterferon alfa-2b. Host, virologic, and treatment factors associated with eradication of HCV
genotype 1 infection were identified. Consistent
with previous observations,14-20 a sustained viro588
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logic response was less frequent among blacks,
persons with advanced hepatic fibrosis and steatosis, and those with high baseline HCV RNA
levels. Although it was not a prespecified covariate, impaired fasting glucose was also associated
with a lower likelihood of sustained virologic response. These data suggest a need for additional
research to test the hypothesis that dietary and
pharmacologic interventions to correct glucose
intolerance can improve treatment response. The
magnitude of HCV RNA suppression during the
treatment phase was also closely linked to the
likelihood of having a sustained virologic response. Among the 10% of patients with undetectable HCV RNA levels at treatment week 4, 86%
had a sustained virologic response. The 24% of
patients with a minimal decline in HCV RNA level
(decline of <1 log10 IU from the baseline value) at
treatment week 4 had a probability of sustained
virologic response of less than 5%. Thus, virologic
response at treatment week 4 is an important predictor of sustained virologic response; HCV RNA
levels should be routinely assessed at this time
point.
The time to the first undetectable HCV RNA
level was associated with the probability of virologic relapse after the end of treatment. Approximately 50% of patients who had HCV suppression
for the first time by treatment week 24 also had
virologic relapse, as compared with less than 10%
of patients who had HCV suppression at treatment
week 4. After week 4, patients receiving peginterferon alfa-2a had a higher rate of HCV RNA suppression than did those who were receiving peg
interferon alfa-2b; however, this difference was
not sustained after the end of the treatment period.
Thus, although the rates of sustained virologic response were similar among the three groups, patients treated with peginterferon alfa-2a were more
likely to have a response while receiving therapy,
followed by relapse after the completion of therapy, whereas patients treated with peginterferon
alfa-2b were more likely to discontinue therapy at
treatment week 12 or 24 because of an insufficient
virologic response.
Increased ribavirin exposure during the treatment phase was associated with an increased
likelihood of sustained virologic response among
all treated patients. Ribavirin exposure was lower
in patients who received peginterferon alfa-2b,
which was administered according to four dosing
categories (based on body weight), as compared
with those who received peginterferon alfa-2a,
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Table 3. Responses to Treatment, According to Treatment Group.*
Low-Dose Peginterferon
Alfa-2b + Ribavirin

Response

Standard-Dose Peginterferon
Alfa-2b + Ribavirin

Peginterferon
Alfa-2a + Ribavirin

number of patients/total number (percent)
Change in HCV RNA between baseline and wk 4
<1 log10 IU

10/304 (3.3)

10/220 (4.5)

11/226 (4.9)

1 to <2 log10 IU

66/249 (26.5)

51/243 (21.0)

67/232 (28.9)

2 to <3 log10 IU

85/151 (56.3)

80/149 (53.7)

72/158 (45.6)

3 to <4 log10 IU

86/113 (76.1)

78/126 (61.9)

91/147 (61.9)

≥4 log10 IU

69/88 (78.4)

76/96 (79.2)

81/124 (65.3)

Undetectable

69/79 (87.3)

107/116 (92.2)

98/123 (79.7)

<1 log10 IU†

1/142 (0.7)

1/91 (1.1)

3/75 (4.0)

1 to <2 log10 IU†

0/160

0/115

1/95 (1.1)

Change in HCV RNA between baseline and wk 12

2 to <3 log10 IU

3/78 (3.8)

4/84 (4.8)

3/71 (4.2)

3 to <4 log10 IU

21/82 (25.6)

19/91 (20.9)

16/96 (16.7)

≥4 log10 IU

55/110 (50.0)

51/127 (40.2)

48/150 (32.0)

303/366 (82.8)

328/407 (80.6)

344/466 (73.8)

75/154 (48.7)

70/157 (44.6)

66/193 (34.2)

Undetectable
HCV RNA at wk 24
≥2 log10 decline from baseline, detectable at wk 12,
and undetectable at wk 24
Weeks to first undetectable HCV RNA level
Sustained virologic response
2

38/42 (90.5)

43/45 (95.6)

37/44 (84.1)

4

33/41 (80.5)

64/72 (88.9)

62/83 (74.7)

12

234/292 (80.1)

227/300 (75.7)

250/355 (70.4)

24

77/157 (49.0)

68/156 (43.6)

72/203 (35.5)

1/43 (2.3)

1/38 (2.6)

Relapse
2

0/38

4

4/37 (10.8)

4/67 (6.0)

6/67 (9.0)

12

27/257 (10.5)

37/263 (14.1)

61/309 (19.7)

24

49/125 (39.2)

62/127 (48.8)

100/171 (58.5)

* The numbers of patients given are those with a sustained virologic response (as prespecified in the statistical analysis plan), except for
weeks to first undetectable hepatitis C virus (HCV) RNA level, for which the number with relapse is also shown. Sustained virologic response was defined as an undetectable HCV RNA level (as measured with the Cobas TaqMan assay [Roche], with a lower limit of detection
of 27 IU per milliliter) at the end of the follow-up period. Relapse was defined as an undetectable HCV RNA level at the end of the treatment
period but a detectable level at the end of the follow-up period. Among the patients with the undetectable HCV RNA levels at treatment
weeks 4 and 12, a sustained virologic response was achieved in 86.2% and 78.7%, respectively. The numbers of patients who had undetectable HCV RNA levels at 12 weeks after the end of treatment but who missed the 24-week post-treatment visit were 38, 21, and 25 for standard-dose peginterferon alfa-2b, low-dose peginterferon alfa-2b, and peginterferon alfa-2a, respectively. Patients with missing HCV RNA
data at weeks 4, 12, or 24 were not included in the analyses.
† According to the protocol, therapy was discontinued in patients with a reduction in HCV RNA level at treatment week 12 that was detectable
and was less than 2 log10 IU or with detectable HCV RNA at week 24; however, in some cases therapy was continued, on the basis of a request by an investigator. A total of 174 patients continued therapy beyond week 12 or 24 despite persistent low-level viremia. Of these patients, a sustained virologic response was achieved in only 14 (5 of 46 patients receiving low-dose peginterferon alfa-2b, 4 of 62 receiving
standard-dose peginterferon alfa-2b, and 5 of 66 receiving peginterferon alfa-2a).

which was administered according to two. Patients peginterferon alfa-2b, as compared with 1200 mg
weighing between 75 and 85 kg received 1000 mg per day if they were also receiving peginterferon
of ribavirin per day if they were also receiving alfa-2a. In this large weight group (792 patients),
n engl j med 361;6
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9 (0.9)
54 (5.3)

Respiratory disorders

Other disorders

98 (9.6)
357 (35.1)

For adverse event

For virologic nonresponse

Use of erythrocyte-stimulating
agent

<8.5 g/dl

<10 g/dl

166 (16.3)

25/1000 (2.5)

21/1008 (2.1)
144 (14.2)

307/1000 (30.7)

28/1000 (2.8)

222/1000 (22.2)

255/1008 (25.3)

21/1008 (2.1)

<500/mm3

Reduced hemoglobin

147/1008 (14.6)

<750/mm3

Reduced neutrophil count

262 (25.7)

129 (12.7)

479 (47.0)

172 (16.6)

39/1034 (3.8)

306/1034 (29.6)

61/1034 (5.9)

279/1034 (27.0)

211 (20.4)

135 (13.0)

414 (40.0)

52 (5.0)

10 (1.0)

14 (1.4)

16 (1.5)

8 (0.8)

30 (2.9)

22 (2.1)

9 (0.9)

8 (0.8)

46 (4.4)

121 (11.7)

6

0.18

0.53

0.007

0.30

<0.001

<0.001

0.03

0.04

0.14

0.61

0.21

0.65

0.03

0.40

0.44

0.80

0.99

0.57

0.63

0.10

0.84

0.10

0.59

0.001

0.01

0.004

0.80

0.001

0.23

0.49

0.36

0.17

0.02

0.04

0.84

0.83

0.26

0.56

0.02

0.78

0.13

0.02

0.03

<0.001

<0.001

<0.001

0.02

<0.001

0.77

0.85

0.73

0.36

0.82

0.23

0.56

0.64

0.26

0.99

0.07

0.06

of

Hematologic events — no./total
no. (%)

523 (51.5)

40 (3.9)

7 (0.7)

19 (1.9)

9 (0.9)

1 (0.1)

16 (1.6)

23 (2.3)

8 (0.8)

4 (0.4)

40 (3.9)

88 (8.6)

5

Low-Dose vs.
Standard-Dose
Low-Dose
Standard-Dose
Peginterferon Alfa-2b
Peginterferon Alfa-2b
Peginterferon Alfa-2b vs. Peginterferon Alfa-2a vs. Peginterferon Alfa-2a

P Value*

n e w e ng l a n d j o u r na l

For any reason

Discontinuation of treatment —
no. (%)

11 (1.1)

Neoplasm
12 (1.2)

7 (0.7)

Infections

Psychiatric disorders

21 (2.1)

Gastrointestinal and hepatobiliary disorders

Nervous-system disorders

7 (0.7)
18 (1.8)

Cardiovascular disorders

4 (0.4)

Hematologic disorders

According to clinical category

94 (9.3)

Treatment-related

1

Any

Serious adverse event —
no. (%)†

Death — no.

Adverse Event

Low-Dose Peginterferon Standard-Dose Peginterferon
Peginterferon
Alfa-2b + Ribavirin
Alfa-2b + Ribavirin
Alfa-2a + Ribavirin
(N = 1016)
(N = 1019)
(N = 1035)

Table 4. Adverse Events, Discontinuations of Treatment, and Dose Reductions, According to Treatment Group.
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* Nominal P values were calculated with the use of a two-sided chi-square test.
† Serious adverse events were classified according to the Medical Dictionary for Regulatory Activities (version 10.1) body-system organ classes.

0.81

0.002
0.002

0.92
0.73

0.94
290 (28.0)

262 (25.3)
262 (25.8)
Irritability

225 (22.1)

197 (19.4)
Depression

256 (25.1)

0.37
0.02
0.001
217 (21.0)

188 (18.5)

260 (25.5)

0.03

<0.001
0.004
<0.001
326 (31.5)

0.02

Neutropenia

263 (25.8)

0.02
0.87
233 (22.5)
270 (26.6)
Myalgia

274 (26.9)

<0.001
<0.001

0.91
0.02

0.26
237 (22.9)

348 (33.6)
345 (33.9)
Anemia

356 (34.9)
331 (32.6)

293 (28.8)

Pyrexia

0.75

0.01

0.16
0.36
0.62
428 (41.4)
401 (39.4)
389 (38.3)
Insomnia

0.005
0.01
377 (36.4)
377 (37.1)
Nausea

433 (42.5)

0.13
0.22

0.001
0.36

0.78
656 (63.4)

438 (42.3)
508 (49.9)
486 (47.8)
Headache

672 (65.9)
676 (66.5)
Fatigue

98 (9.6)
Common adverse events (≥25%
incidence) — no. (%)

0.69

0.004
0.48
<0.001
142 (13.7)

<0.001

Of both

151 (14.8)

0.57
0.34
180 (17.4)
170 (16.7)
Of ribavirin only

187 (18.4)

0.22

0.86
<0.001

0.009
122 (11.8)

444 (42.9)

70 (6.9)
Of peginterferon alfa only

441 (43.3)
338 (33.3)
Any

Dose modification — no. (%)

103 (10.1)

<0.001

Peginterferon Alfa-2b vs. Alfa-2a for Hepatitis C

the rate of sustained virologic response was higher
by approximately 10 percentage points in the peg
interferon alfa-2a group, suggesting that the ribavirin dose for persons who weigh between 75 and
85 kg should be 1200 mg per day in the peginter
feron alfa-2b groups. Surprisingly, reducing the
ribavirin dose because of treatment-related anemia
(as was done in 30% of patients) did not appear
to reduce the likelihood of sustained virologic response. Despite the reduction of ribavirin dose by
as much as 50% in patients receiving peginterferon
alfa-2a, patients with anemia had a higher rate
of sustained virologic response than did those
without anemia, suggesting that the magnitude
of anemia may be a pharmacodynamic marker of
drug exposure. The data indicate that the initial
ribavirin dose should be at least 13 mg per kilogram per day and that the conservative management of anemia, involving a ribavirin-dose reduction in either one or two steps, appears to maintain
safety and not to compromise efficacy.
The findings are subject to several limitations.
Because the initial ribavirin dose varied among the
patients, the study compares HCV treatment regimens and is not a direct comparison of the type
of peginterferon. Nonetheless, more than 51% of
patients received the same dose of ribavirin in
combination with either peginterferon alfa-2a or
peginterferon alfa-2b, and their rates of sustained
virologic response were similar. Second, the procedure for ribavirin-dose reduction differed between the peginterferon alfa-2a group and the
peginterferon alfa-2b groups. Yet, the rate of sustained virologic response was higher among patients who had the ribavirin dose reduced because
of anemia than among those who did not. Third,
since the study was conducted in the United States,
these comparative data may not be generalizable
to other regions or HCV genotypes. Fourth, owing
to insurmountable differences in drug formulation
(lyophilized powder in the case of peginterferon
alfa-2b or solution in the case of peginterferon
alfa-2a), patients and investigators were aware of
the type of peginterferon being given. After careful inspection, however, no irregularity in data
collection or reporting was detected.
In conclusion, the rates of sustained virologic
response and the safety and adverse-event profiles
were similar among patients infected with HCV
genotype 1 who received standard-dose or lowdose peginterferon alfa-2b or peginterferon alfa-2a,
in combination with ribavirin.
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